top of page
Search

Intelligent Bio Solutions (NASDAQ: INBS)

  • Writer: Jimmy Lederer
    Jimmy Lederer
  • Apr 24
  • 5 min read

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on advancing non invasive drug testing solutions through proprietary fingerprint sweat analysis technology. The company’s strategy centers on transforming traditional drug screening by replacing urine and saliva based methods with rapid hygienic and cost efficient alternatives that deliver actionable real time insights into recent drug use. Intelligent Bio Solutions is focused on enabling employers and institutions to better assess impairment and fitness for duty through a detection window of approximately 16 to 24 hours which more accurately reflects current use rather than historical consumption. The company’s core business is built around its Intelligent Fingerprinting Drug Screening System a portable platform that delivers results in under ten minutes while preserving user dignity and eliminating the need for specialized facilities or invasive collection procedures. This system is designed to detect commonly used substances including opiates cocaine methamphetamine and cannabis and is supported by a growing installed base across global markets. Intelligent Bio Solutions also offers its SmarTest wearable patch which enables continuous drug monitoring over a 7 to 10 day period expanding the company’s reach into rehabilitation law enforcement and long term compliance applications. Operating within a large and growing global drug screening market the company is targeting increased adoption driven by workplace safety requirements regulatory expansion and rising substance use trends. Intelligent Bio Solutions has established a presence across more than 27 countries with hundreds of active accounts and is advancing regulatory initiatives including planned entry into the United States market. Through its focus on non invasive diagnostics scalable testing solutions and recurring revenue from consumables Intelligent Bio Solutions offers investors exposure to the modernization of drug screening technologies the expansion of workplace and public safety infrastructure and the broader shift toward faster more efficient and accessible testing systems.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on advancing non invasive drug testing solutions through proprietary fingerprint sweat analysis technology. The company’s strategy centers on transforming traditional drug screening by replacing urine and saliva based methods with rapid hygienic and cost efficient alternatives that deliver actionable real time insights into recent drug use. Intelligent Bio Solutions is focused on enabling employers and institutions to better assess impairment and fitness for duty through a detection window of approximately 16 to 24 hours which more accurately reflects current use rather than historical consumption. The company’s core business is built around its Intelligent Fingerprinting Drug Screening System a portable platform that delivers results in under ten minutes while preserving user dignity and eliminating the need for specialized facilities or invasive collection procedures. This system is designed to detect commonly used substances including opiates cocaine methamphetamine and cannabis and is supported by a growing installed base across global markets. Intelligent Bio Solutions also offers its SmarTest wearable patch which enables continuous drug monitoring over a 7 to 10 day period expanding the company’s reach into rehabilitation law enforcement and long term compliance applications. Operating within a large and growing global drug screening market the company is targeting increased adoption driven by workplace safety requirements regulatory expansion and rising substance use trends. Intelligent Bio Solutions has established a presence across more than 27 countries with hundreds of active accounts and is advancing regulatory initiatives including planned entry into the United States market. Through its focus on non invasive diagnostics scalable testing solutions and recurring revenue from consumables Intelligent Bio Solutions offers investors exposure to the modernization of drug screening technologies the expansion of workplace and public safety infrastructure and the broader shift toward faster more efficient and accessible testing systems.

Intelligent Bio Solutions Inc. (NASDAQ: INBS)

A medical technology company focused on advancing non invasive drug testing solutions through proprietary fingerprint sweat analysis with a strategy centered on replacing traditional urine and saliva based screening with rapid cost efficient and real time detection methods that improve workplace safety regulatory compliance and operational efficiency across multiple industries. The company’s platform is anchored by its Intelligent Fingerprinting Drug Screening System a portable solution designed to detect recent drug use through sweat providing actionable insights into impairment while eliminating invasive collection procedures.


Market Focus

Intelligent Bio Solutions operates within the global drug screening and diagnostics market targeting applications across workplace safety healthcare law enforcement and compliance driven environments. As substance use rates rise and regulatory standards tighten demand is increasing for faster more reliable and non invasive testing solutions. The company is positioned to benefit from structural tailwinds including expanded workplace testing requirements increased adoption of point of care diagnostics and a shift toward technologies that prioritize real time detection accuracy and user convenience.


Platform and Strategy

Intelligent Bio Solutions’ operating model is built on three core pillars.

• Advance and scale non invasive fingerprint based drug testing technology focused on detecting recent drug use.

• Expand commercial adoption across global markets through portable efficient and cost effective testing solutions.

• Develop complementary monitoring technologies to broaden use cases and increase recurring revenue opportunities.


Asset Base and Development

• Flagship Intelligent Fingerprinting Drug Screening System delivering results in under ten minutes.

• Detection of commonly used substances including opiates cocaine methamphetamine and cannabis.

• Focus on a 16 to 24 hour detection window to assess real time impairment rather than historical use.

• Portable and hygienic system eliminating the need for invasive sample collection and specialized facilities.


Operational Advancement

• Continued expansion of installed base and active customer accounts across multiple countries.

• Ongoing development and validation of testing capabilities to support broader regulatory acceptance.

• Progress toward United States market entry and regulatory approvals.

• Strengthening of intellectual property portfolio supporting long term competitive positioning.


Exploration and Growth Pipeline

• Advancement of the SmarTest wearable patch for continuous drug monitoring over a 7 to 10 day period.

• Expansion into rehabilitation compliance monitoring and long term testing applications.

• Development of additional testing panels and capabilities across a wider range of substances.

• Scalable platform aligned with increasing global demand for rapid and non invasive diagnostics.


Partnerships and Strategic Positioning

Intelligent Bio Solutions works with commercial partners distributors and regulatory bodies to expand adoption and market access. The company benefits from growing demand for workplace safety solutions and is strategically positioned to support industries requiring fast reliable and non invasive testing while leveraging global distribution channels and regulatory pathways.


Leadership and Capital Strategy

The company’s leadership team brings experience across medical technology diagnostics and commercialization. Its capital strategy focuses on scaling adoption of its platform expanding recurring revenue through consumables and advancing regulatory milestones to unlock larger addressable markets including the United States.


Near Term Catalysts

• Continued growth in customer accounts and installed systems.

• Progress toward regulatory clearance and United States market entry.

• Expansion of testing capabilities and product offerings.

• Increased adoption across workplace and compliance driven industries.


Conclusion

Intelligent Bio Solutions is executing a strategy centered on transforming drug screening through non invasive rapid testing technology. With exposure to growing demand for workplace safety solutions regulatory compliance and modern diagnostics the company offers investors participation in the evolution of drug testing infrastructure and the broader shift toward faster more efficient and accessible healthcare technologies.


Jimmy Lederer

Vice President

Trinity Financing Investments Corporation

Phone: 347-514-0000

All content provided is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect to any products or services. The content presented should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. There are inherent risks involved with investing in Issuers, as set out in the public disclosure record of each Issuer. Issuers are not responsible for revising or updating any information that they present via TFIC events.


Investors should refer to the continuous disclosure documents filed by each Issuer under applicable securities laws, including risk factors and warnings regarding “forward looking information”. Issuers are solely responsible for compliance with applicable securities laws, and TFIC makes no representations and provides no assurances to Investors regarding the accuracy or truthfulness of information presented by Issuers via TFIC events or in their public disclosure records. 


TFIC does not recommend or endorse any Issuer that presents via TFIC events, nor does TFIC verify the accuracy of any information presented by Issuers to Investors via TFIC events or in their public disclosure records. TFIC’s sole responsibility as the operator of TFIC events is to provide a platform for Investors and Issuers to communicate directly.


ALL CONTENT PRESENTED BY ISSUER(S) IS PROVIDED BY THE ISSUER(S) "AS IS" AND “AS AVAILABLE”. TFIC DOES NOT GUARANTEE THE ACCURACY OF ITS CONTENT. BY ATTENDING, EACH INVESTOR AGREES TO ACCEPT ANY RISKS ASSOCIATED AND ACKNOWLEDGES THAT TFIC IS NOT RESPONSIBLE FOR ANY CONTENT PRESENTED BY OR RELATING TO ISSUERS ON THE PLATFORM. 


TFIC DOES NOT WARRANT THAT THE PROVISION OF INFORMATION BY ISSUERS IN THEIR PRESENTATION WILL BE ERROR-FREE, TIMELY, COMPLETE OR ACCURATE. ATTENDANCE AND RELIANCE ON INFORMATION RECIEVED THEREON IS AT INVESTOR’S SOLE RISK. TFIC WILL NOT BE IN ANY WAY BE LIABLE TO ANY INVESTOR OR ISSUER OR ANY OTHER ENTITY OR PERSON FOR ANY INACCURACIES, ERRORS, OMISSIONS, DELAYS, DAMAGES, CLAIMS, LIABILITIES OR LOSSES, REGARDLESS OF CAUSE, IN OR ARISING FROM THE USE OF THE PLATFORM.


IN NO EVENT WILL TFIC BE LIABLE FOR ANY DAMAGES, INCLUDING WITHOUT LIMITATION DIRECT OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES ARISING IN CONNECTION WITH THE ATTENDANCE BY INVESTORS AND/OR ISSUERS EVEN IF TFIC IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES OR EXPENSES. FURTHER, TFIC SHALL NOT BE LIABLE IN ANY MANNER FOR THE PRODUCT OR SERVICES OF ANYONE WHO REDISTRIBUTES THE INFORMATION PROVIDED ON THE PLATFORM, AND SUCH REDISTRIBUTION IS EXPRESSLY PROHIBITED.



 
 

SOCIALS

  • LinkedIn

Trinity Financing Investments Corporation "TFIC"

bottom of page